Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1542/peds.109.1.158 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in Electrochemical Nitrite Reduction toward Nitric Oxide Synthesis for Biomedical Applications.
Adv Healthc Mater
January 2025
Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Nitric oxide (NO) is an essential molecule in biomedicine, recognized for its antibacterial properties, neuronal modulation, and use in inhalation therapies. The effectiveness of NO-based treatments relies on precise control of NO concentrations tailored to specific therapeutic needs. Electrochemical generation of NO (E-NOgen) via nitrite (NO ) reduction offers a scalable and efficient route for controlled NO production, while also addressing environmental concerns by reducing NO pollution and maintaining nitrogen cycle balance.
View Article and Find Full Text PDFOxidative and nitrative DNA damage induced by industrial chemicals in relation to carcinogenesis.
J Occup Health
January 2025
Department of Environmental Health, University of Fukui School of Medical Science, Eiheiji, Fukui, Japan.
Objectives: Many chemicals have been used for industrial purposes, and some of them are carcinogenic to humans. However, their molecular mechanisms have not been well understood. Reactive oxygen species are generated from industrial chemicals and contribute to carcinogenesis.
View Article and Find Full Text PDFUse, Benefits, and Adverse Effects of Inhaled Nitric Oxide During Anesthesia.
Ann Card Anaesth
January 2025
Department of Surgery, Division of Anesthesiology, Hospital das Clínicas de Belo Horizonte, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Inhaled corticosteroids in asthma and chronic obstructive pulmonary disease combined phenotype: when to use and what to expect?
Monaldi Arch Chest Dis
January 2025
Department of Community Medicine, K.S. Hegde Medical College, Deralakatte, Karnataka.
The term "asthma-chronic obstructive pulmonary disease (COPD) combined phenotype" describes patients with persistent airflow limitation and features of both asthma and COPD. There is a lack of data on effective treatments for this group, often excluded from asthma or COPD trials. Inhaled corticosteroids (ICS) are standard for asthma, while bronchodilators are key for COPD.
View Article and Find Full Text PDFBiologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI).
World Allergy Organ J
January 2025
Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy.
Background: This study aimed to evaluate the impact of severe asthma (SA) treatments after 12 months in achieving clinical remission (CR) within the context of the Severe Asthma Network in Italy (SANI) using the recent SANI definition of CR on treatment.
Methods: CR has been defined by SANI as complete, partial, and no CR. Complete CR is defined by the absence of oral corticosteroids (OCS), no symptoms, no exacerbations, and stable lung function, and partial CR requires the absence of OCS and the fulfillment of 2 out of the other 3 criteria.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!